ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Cleveland, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Endometrial Cancer
Ovarian Epithelial Carcinoma
Breast Cancer
Cancer
Fallopian Tube Cancer
Non-Small-Cell Lung Carcinoma
Triple Negative Breast Cancer

Ovarian Cancer trials near Cleveland, OH, USA:

Locations recently updated

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

Gleolan for the real-time detection and visualization of epithelial ovarian cancer tumors during debulking surgery. The st...

Enrolling
Ovarian Cancer
Drug: Gleolan

Phase 3

NX Development

Cleveland, Ohio, United States and 10 other locations

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

To see how effective the study medicine combined with hormone therapy is when given to participants with recurrent low-grade serous ovarian ....

Enrolling
Serous Ovarian Cancer
Ovarian Cancer
Drug: Regorafenib
Drug: Fulvestrant

Phase 2

Sarah K. Lynam MD

Cleveland, Ohio, United States

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objecti ...

Enrolling
Primary Peritoneal Cancer
Platinum-refractory Ovarian Cancer
Drug: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin
Drug: Platinum chemotherapy: carboplatin (preferred) or cisplatin

Phase 3

Genelux

Cleveland, Ohio, United States and 31 other locations

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients (DUO-O)

followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...

Active, not recruiting
Advanced Ovarian Cancer
Drug: Bevacizumab
Drug: Durvalumab placebo

Phase 3

AstraZeneca
AstraZeneca

Cleveland, Ohio, United States and 213 other locations

A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation (RAMP 201)

the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...

Active, not recruiting
Low Grade Ovarian Serous Adenocarcinoma
Ovarian Cancer
Drug: avutometinib (VS-6766) and defactinib
Drug: avutometinib (VS-6766)

Phase 2

Verastem

Cleveland, Ohio, United States and 46 other locations

A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian...

Enrolling
Refractory Ovarian Carcinoma
Platinum-resistant Ovarian Cancer
Drug: CBX-12

Phase 2

Cybrexa Therapeutics

Cleveland, Ohio, United States and 16 other locations

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting
Advanced Ovarian Cancer
FIGO Stage III-IV
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Cleveland, Ohio, United States and 176 other locations

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer (RAINFOL-02)

study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already ...

Active, not recruiting
Platinum-resistant Ovarian Cancer
Drug: Topotecan
Drug: Gemcitabine

Phase 3

Genmab
Genmab

Cleveland, Ohio, United States and 176 other locations

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301)

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...

Enrolling
Low Grade Serous Ovarian Cancer
Drug: Defactinib
Drug: Letrozole

Phase 3

Verastem

Cleveland, Ohio, United States and 106 other locations

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

outcome of ADP A2M4CD8 as monotherapy and in combination treatment with nivolumab in human leukocyte antigen (HLA) A2+ subjects with recurrent ovarian...

Active, not recruiting
Ovarian Cancer
Genetic: Autologous genetically modified ADP-A2M4CD8 cells
Combination Product: Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab

Phase 2

USWM CT, LLC

Cleveland, Ohio, United States and 22 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems